US EditionPublished • loading... • Updated
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray
Use of Aptar Pharma’s UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infectionsCRYSTAL LAKE, Ill,--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) Powder [...] The post Aptar’s…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
